New respiratory syncytial virus immunization products in low- and middle-income countries: potential for cost-effective impact on a high burden of disease in young infants
As new, efficacious respiratory syncytial virus (RSV) immunization products reach the market, affordable pricing as well as improved estimation of disease burden and the full potential and cost effectiveness of RSV prevention in the hardest hit geographies in low- and middle-income countries are cri...
Saved in:
| Published in: | BMC medicine Vol. 21; no. 1; pp. 177 - 3 |
|---|---|
| Main Authors: | , |
| Format: | Journal Article |
| Language: | English |
| Published: |
London
BioMed Central
15.05.2023
BioMed Central Ltd Springer Nature B.V BMC |
| Subjects: | |
| ISSN: | 1741-7015, 1741-7015 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | As new, efficacious respiratory syncytial virus (RSV) immunization products reach the market, affordable pricing as well as improved estimation of disease burden and the full potential and cost effectiveness of RSV prevention in the hardest hit geographies in low- and middle-income countries are critical to inform country adoption and enable maximum impact against infant disease and mortality globally. The data reported in the special issue underscore the enormous burden, and associated cost, of RSV disease in young infants in several LMICs, including Kenya and South Africa, as well as the potential for RSV maternal vaccines or long-acting monoclonal antibodies, to be cost-effective and possibly even cost-saving. |
|---|---|
| AbstractList | Abstract As new, efficacious respiratory syncytial virus (RSV) immunization products reach the market, affordable pricing as well as improved estimation of disease burden and the full potential and cost effectiveness of RSV prevention in the hardest hit geographies in low- and middle-income countries are critical to inform country adoption and enable maximum impact against infant disease and mortality globally. The data reported in the special issue underscore the enormous burden, and associated cost, of RSV disease in young infants in several LMICs, including Kenya and South Africa, as well as the potential for RSV maternal vaccines or long-acting monoclonal antibodies, to be cost-effective and possibly even cost-saving. As new, efficacious respiratory syncytial virus (RSV) immunization products reach the market, affordable pricing as well as improved estimation of disease burden and the full potential and cost effectiveness of RSV prevention in the hardest hit geographies in low- and middle-income countries are critical to inform country adoption and enable maximum impact against infant disease and mortality globally. The data reported in the special issue underscore the enormous burden, and associated cost, of RSV disease in young infants in several LMICs, including Kenya and South Africa, as well as the potential for RSV maternal vaccines or long-acting monoclonal antibodies, to be cost-effective and possibly even cost-saving.As new, efficacious respiratory syncytial virus (RSV) immunization products reach the market, affordable pricing as well as improved estimation of disease burden and the full potential and cost effectiveness of RSV prevention in the hardest hit geographies in low- and middle-income countries are critical to inform country adoption and enable maximum impact against infant disease and mortality globally. The data reported in the special issue underscore the enormous burden, and associated cost, of RSV disease in young infants in several LMICs, including Kenya and South Africa, as well as the potential for RSV maternal vaccines or long-acting monoclonal antibodies, to be cost-effective and possibly even cost-saving. As new, efficacious respiratory syncytial virus (RSV) immunization products reach the market, affordable pricing as well as improved estimation of disease burden and the full potential and cost effectiveness of RSV prevention in the hardest hit geographies in low- and middle-income countries are critical to inform country adoption and enable maximum impact against infant disease and mortality globally. The data reported in the special issue underscore the enormous burden, and associated cost, of RSV disease in young infants in several LMICs, including Kenya and South Africa, as well as the potential for RSV maternal vaccines or long-acting monoclonal antibodies, to be cost-effective and possibly even cost-saving. As new, efficacious respiratory syncytial virus (RSV) immunization products reach the market, affordable pricing as well as improved estimation of disease burden and the full potential and cost effectiveness of RSV prevention in the hardest hit geographies in low- and middle-income countries are critical to inform country adoption and enable maximum impact against infant disease and mortality globally. The data reported in the special issue underscore the enormous burden, and associated cost, of RSV disease in young infants in several LMICs, including Kenya and South Africa, as well as the potential for RSV maternal vaccines or long-acting monoclonal antibodies, to be cost-effective and possibly even cost-saving. Keywords: Respiratory syncytial virus, Maternal vaccine, Infant monoclonal antibody, Burden, Cost effectiveness, Low- and middle-income countries In Kenya, where the focus was on the cost of taking care of a child hospitalized with severe RSV lower respiratory tract infection (LRTI), the total mean cost to both health system and household ranged from USD 119 per episode in Kilifi District, where the KEMRI-Wellcome Trust Programme (KWTRP) provides significant external financial support for delivery of pediatric medical services, to USD 527 in Siaya District, which relies on user fees and national government support, and might be more representative of other regions of Kenya (Nyiro et al.) In South Africa, investigators utilized their RSV burden data analysis to further estimate the cost of RSV illness in children < 5 years at the national level to be greater than USD $137 million. Stratification of these costs by granular age bands revealed that the greatest financial burden of RSV illness is in the first 6 months of life, with the highest cost associated with the first 2 months of life—again underscoring the potential benefit of maternal vaccines and mAbs that demonstrate greatest impact in this age group. A systematic review of published RSV cost of illness studies reveals an overall paucity of data from LMICs, but similarly indicates high out-of-pocket costs to the family in Bangladesh and Malawi, 24% and 32% of monthly household income, respectively (Wittenauer et al. https://doi.org/10.1186/s12916-023-02792-z). Utilizing the reported RSVPreF maternal vaccine phase 3 efficacy (81.8% against severe RSV disease at 90 days) [2] and assuming a dose price of $USD 5, the analysis showed a favorable incremental cost effectiveness ratio (ICER) of USD $180 per disability-adjusted life year (DALY) averted in Kenya. |
| ArticleNumber | 177 |
| Audience | Academic |
| Author | Srikantiah, Padmini Klugman, Keith P. |
| Author_xml | – sequence: 1 givenname: Padmini surname: Srikantiah fullname: Srikantiah, Padmini email: padmini.srikantiah@gatesfoundation.org organization: Pneumonia Program, Global Health Division, Bill & Melinda Gates Foundation – sequence: 2 givenname: Keith P. surname: Klugman fullname: Klugman, Keith P. organization: Pneumonia Program, Global Health Division, Bill & Melinda Gates Foundation |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37183242$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ks1u1DAUhSNURH_gBVggS0iITUpsJ7HDBlUVP5Uq2MDacp3rGVeJPdhO2-GVeEluZlraQaiKolj2Od91js5hseeDh6J4SatjSmX7LlHW0basGMdXSl7ePCkOqKhpKSra7D1Y7xeHKV1WFWuEqJ8V-1xQyVnNDorfX-GaREgrF3UOcU3S2pt1dnogVy5OibhxnLz7pbMLnqxi6CeTcdeTIVyXRPuejK7vByidN2EEYsLkc3SQ3pNVyOA3KBsiHqRcgrVgsrsC5K60yQShmizdYkkuptiDJ8GS3iXQCeYha6QtcGG1z-l58dTqIcGL2-9R8ePTx--nX8rzb5_PTk_OS9O0XS51Y23ddYyzXohWtgzDqnXVScFFJ4Q0fQdALW-rlmFuDTWs6nVrKm3q7oIZflScbbl90JdqFd2o41oF7dRmI8SF0jE7M4BqraS6wfAlt7WgVkvTtabROIrjZSyyPmxZq-lihN5gIFEPO9DdE--WahGuFK3w1ryrkfD2lhDDzwlSVqNLBoZBewhTUkxSLqVgQqD09T_SyzBFj1nNqqZlTLT8XrXQ-AeYbcDBZoaqE1F3fA5mVh3_R4VPD6MzWETrcH_H8OaBYQl6yMsUhmkuTtoVvnoYyd8s7kqJArkVmBhSimCVcXlTQLyCGzAaNfdfbfuvsP9q0391g1b2j_WO_qiJb00JxX4B8T62R1x_AIGqGMY |
| CitedBy_id | crossref_primary_10_1002_jmv_29453 crossref_primary_10_1038_s41541_023_00734_7 crossref_primary_10_1038_s41598_024_79407_x crossref_primary_10_2500_aap_2024_45_230089 |
| Cites_doi | 10.1016/S2352-4642(22)00321-2 10.1056/NEJMoa2110275 10.1093/cid/ciab481 10.1016/S0140-6736(22)00478-0 10.1056/NEJMoa2216480 10.1056/NEJMoa1908380 10.1111/irv.12688 10.1016/S2214-109X(20)30251-5 10.1093/cid/ciab486 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2023 2023. The Author(s). COPYRIGHT 2023 BioMed Central Ltd. 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2023 – notice: 2023. The Author(s). – notice: COPYRIGHT 2023 BioMed Central Ltd. – notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7U9 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR C1K CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P M7N PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM DOA |
| DOI | 10.1186/s12916-023-02883-x |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central Environmental Sciences and Pollution Management ProQuest One ProQuest Central ProQuest Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Proquest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Environmental Sciences and Pollution Management ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database CrossRef MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: ProQuest Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1741-7015 |
| EndPage | 3 |
| ExternalDocumentID | oai_doaj_org_article_6f81a528883f471fa8c96c5a7373569f PMC10184394 A749336063 37183242 10_1186_s12916_023_02883_x |
| Genre | Research Support, Non-U.S. Gov't Editorial Commentary |
| GeographicLocations | South Africa Kenya |
| GeographicLocations_xml | – name: South Africa – name: Kenya |
| GrantInformation_xml | – fundername: Bill and Melinda Gates Foundation funderid: http://dx.doi.org/10.13039/100000865 – fundername: ; |
| GroupedDBID | --- 0R~ 23N 2WC 4.4 53G 5GY 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR IHW INH INR ITC KQ8 M1P M48 MK0 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP WOQ WOW XSB AAYXX AFFHD CITATION -5E -5G -A0 -BR 3V. ACRMQ ADINQ ALIPV C24 CGR CUY CVF ECM EIF NPM 7QL 7U9 7XB 8FK AZQEC C1K DWQXO H94 K9. M7N PKEHL PQEST PQUKI 7X8 5PM |
| ID | FETCH-LOGICAL-c569t-a5ff499232d7768621184a0987379778cd9ee1f3606202851c20da6c0ac49b2c3 |
| IEDL.DBID | 7X7 |
| ISICitedReferencesCount | 5 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000988612500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1741-7015 |
| IngestDate | Fri Oct 03 12:52:27 EDT 2025 Tue Nov 04 02:08:04 EST 2025 Fri Sep 05 12:20:47 EDT 2025 Wed Oct 08 14:30:45 EDT 2025 Tue Nov 11 10:25:58 EST 2025 Tue Nov 04 17:19:58 EST 2025 Thu May 22 20:45:56 EDT 2025 Thu Jan 02 22:52:30 EST 2025 Tue Nov 18 22:20:03 EST 2025 Sat Nov 29 04:08:30 EST 2025 Sat Sep 06 07:24:52 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Maternal vaccine Infant monoclonal antibody Respiratory syncytial virus Burden Cost effectiveness Low- and middle-income countries |
| Language | English |
| License | 2023. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c569t-a5ff499232d7768621184a0987379778cd9ee1f3606202851c20da6c0ac49b2c3 |
| Notes | SourceType-Scholarly Journals-1 content type line 14 ObjectType-Editorial-2 ObjectType-Commentary-1 content type line 23 ObjectType-Article-3 |
| OpenAccessLink | https://www.proquest.com/docview/2815622763?pq-origsite=%requestingapplication% |
| PMID | 37183242 |
| PQID | 2815622763 |
| PQPubID | 42775 |
| PageCount | 3 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_6f81a528883f471fa8c96c5a7373569f pubmedcentral_primary_oai_pubmedcentral_nih_gov_10184394 proquest_miscellaneous_2813887277 proquest_journals_2815622763 gale_infotracmisc_A749336063 gale_infotracacademiconefile_A749336063 gale_healthsolutions_A749336063 pubmed_primary_37183242 crossref_citationtrail_10_1186_s12916_023_02883_x crossref_primary_10_1186_s12916_023_02883_x springer_journals_10_1186_s12916_023_02883_x |
| PublicationCentury | 2000 |
| PublicationDate | 2023-05-15 |
| PublicationDateYYYYMMDD | 2023-05-15 |
| PublicationDate_xml | – month: 05 year: 2023 text: 2023-05-15 day: 15 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC medicine |
| PublicationTitleAbbrev | BMC Med |
| PublicationTitleAlternate | BMC Med |
| PublicationYear | 2023 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | P Srikantiah (2883_CR5) 2021; 73 LL Hammitt (2883_CR3) 2022; 386 HJ Zar (2883_CR8) 2020; 8 EAF Simões (2883_CR4) 2023; 7 Y Li (2883_CR1) 2022; 399 2883_CR2 EAF Simões (2883_CR6) 2021; 73 S Hirve (2883_CR7) 2020; 14 SA Madhi (2883_CR9) 2020; 30 |
| References_xml | – volume: 7 start-page: 180 year: 2023 ident: 2883_CR4 publication-title: Lancet Child Adolesc Health doi: 10.1016/S2352-4642(22)00321-2 – volume: 386 start-page: 837 year: 2022 ident: 2883_CR3 publication-title: N Engl J Med doi: 10.1056/NEJMoa2110275 – volume: 73 start-page: S193 year: 2021 ident: 2883_CR6 publication-title: India Clin Infect Dis doi: 10.1093/cid/ciab481 – volume: 399 start-page: 2047 year: 2022 ident: 2883_CR1 publication-title: Lancet doi: 10.1016/S0140-6736(22)00478-0 – ident: 2883_CR2 doi: 10.1056/NEJMoa2216480 – volume: 30 start-page: 426 year: 2020 ident: 2883_CR9 publication-title: N Engl J Med doi: 10.1056/NEJMoa1908380 – volume: 14 start-page: 647 year: 2020 ident: 2883_CR7 publication-title: Influenza Other Respir Viruses doi: 10.1111/irv.12688 – volume: 8 start-page: e1316 year: 2020 ident: 2883_CR8 publication-title: Lancet Glob Health doi: 10.1016/S2214-109X(20)30251-5 – volume: 73 start-page: S177 year: 2021 ident: 2883_CR5 publication-title: Clin Infect Dis doi: 10.1093/cid/ciab486 |
| SSID | ssj0025774 |
| Score | 2.4048586 |
| Snippet | As new, efficacious respiratory syncytial virus (RSV) immunization products reach the market, affordable pricing as well as improved estimation of disease... In Kenya, where the focus was on the cost of taking care of a child hospitalized with severe RSV lower respiratory tract infection (LRTI), the total mean cost... Abstract As new, efficacious respiratory syncytial virus (RSV) immunization products reach the market, affordable pricing as well as improved estimation of... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 177 |
| SubjectTerms | Age Babies Biomedicine Burden Care and treatment Control Cost analysis Cost effectiveness Cost of Illness Cost-Benefit Analysis Data analysis Developing Countries Disease prevention Dosage and administration Editorial Health care expenditures Hospitalization Households Humans Identification and classification Illnesses Immunization Income Infant Infant monoclonal antibody Infants (Newborn) Low- and middle-income countries Maternal vaccine Medicine Medicine & Public Health Monoclonal antibodies Mortality Pediatrics Pneumonia Public health Respiratory diseases Respiratory syncytial virus Respiratory Syncytial Virus Infections - epidemiology Respiratory Syncytial Virus Infections - prevention & control Respiratory Syncytial Virus Vaccines Respiratory Syncytial Virus, Human Respiratory tract Respiratory tract diseases Strengthening the evidence base to evaluate preventive interventions against respiratory syncytial virus (RSV) Surveillance Vaccines |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELVQhRAXxDcpBYyExAGsJvYmtrkVRMUBKg6AerMcxxYrbbOrTba0v4k_yYydbJsi4MJtFU-y8cz42RPPPBPyQgivNS8syxutGACeYqqGcWWVqG3ZSOUj2-e3j_LoSB0f68-XjvrCnLBED5wUt18FVdiSQ6AmAgBpsMrpypVWCinKSgdE31zqMZgaQq0SVjVjiYyq9juY1QpMtsU9S3gSO5tMQ5Gt_3dMvjQpXU2YvLJrGiejw9vk1rCKpAfp7e-Qa769S258GvbJ75GfgF10fbGLTrtzAFEYzAt6Ol9vOjqPZSGpBJOuEusrXG3pYvmDUds29CR-uWBI3nDiaTxSAqPqN3S17DHDCB4F611o6HqWkkIAN2kquqTwUEuRCZnWsUyCLgMdtoLwT84RYuBHwCSc--Tr4fsv7z6w4VgG5kDhPbNlCBAnwVKskRILTEDFM5trBSaB1aRyjfa-CAJCIw7aLgvH88ZWLrdupmvuxAOy0y5b_4hQ1ZR1LoOsc-Fn3AvrdV0XOkihGzxUKyPFaCXjBs5yPDpjYWLsoiqTLGvAsiZa1pxl5NX2nlVi7Pir9Fs0_lYS2bbjBfBBM_ig-ZcPZuQZuo5JpatbzDAHcqYF6gE68jJKIGpAB5wdih9ADci_NZHcm0jCaHfT5tE9zYA2neFI-cO5xObn22a8EzPoWr_cRBkBEwqXMiMPkzdvOy0kAvuMZ0RN_HyilWlLO_8euciR8A2LqzPyehwSF-_1Z7Xv_g-1PyY3eRzSJSvKPbLTrzf-CbnuTvt5t34aAeEXD8VjZw priority: 102 providerName: Directory of Open Access Journals – databaseName: Springer LINK dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZQQYgL70eggJGQOIDVxN7ENreCqDhAhXhUvVmOY8NK22S12S30N_EnmXEeJeUhwW0Vj7Prseeb8XrmMyGPhfBa88yytNKKAeAppkqwK6tEafNKKh_ZPg_eyP19dXio3_VFYe2Q7T4cSUakjmatip0WPFOGCbN47qiUYBA5ngd3p_DChvcfDsZtVg4RzVAe89t-ExcUmfp_xeOfHNLZZMkzJ6bREe1d-b8hXCWX-8CT7nYr5Ro55-vr5OLb_mj9BvkOcEdXpwfvtD0B3AX7X9Dj-WrT0nmsJOmqNumyI4qFpzVdNF8ZtXVFj-KfHQz5Ho48jbdQ4Eb8OV02a0xKgldBiAwN7Zp1eSQAtbSr06TwUkuRPJmWsbKCNoH2p0f4JSeISvAhYN7OTfJp79XHl69Zf5MDc3mh18zmIcDWCqK3SkqsSQF1zCzMnRQSAlDlKu19FgTspjhoJs8cTytbuNS6mS65E7fIVt3U_g6hqsrLVAZZpsLPuBfW67LMdJBCV3gPV0KyYXKN62nO8baNhYnbHVWYbhYMzIKJs2C-JeTp2GfZkXz8VfoFrplREgm644Nm9dn09m6KoDKbQwclAvj_YJXThcstDFiASkJCHuKKM1216wgzZlfOtEA9wECeRAkEGhiAs329BKgBKbsmktsTSQAIN20eVrXpAao1HFmCOJfY_Ghsxp6YdFf7ZhNlBPggLmVCbndGMA5aSPQFM54QNTGPiVamLfX8S6QvR444rMdOyLPBSk5_15_VfvffxO-RSzwaWs6yfJtsrVcbf59ccMfrebt6EBHjB3xBaS0 priority: 102 providerName: Springer Nature |
| Title | New respiratory syncytial virus immunization products in low- and middle-income countries: potential for cost-effective impact on a high burden of disease in young infants |
| URI | https://link.springer.com/article/10.1186/s12916-023-02883-x https://www.ncbi.nlm.nih.gov/pubmed/37183242 https://www.proquest.com/docview/2815622763 https://www.proquest.com/docview/2813887277 https://pubmed.ncbi.nlm.nih.gov/PMC10184394 https://doaj.org/article/6f81a528883f471fa8c96c5a7373569f |
| Volume | 21 |
| WOSCitedRecordID | wos000988612500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMed Central Open Access Free customDbUrl: eissn: 1741-7015 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: RBZ dateStart: 20030101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1741-7015 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: DOA dateStart: 20030101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1741-7015 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: M~E dateStart: 20030101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1741-7015 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1741-7015 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Publicly Available Content Database customDbUrl: eissn: 1741-7015 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1741-7015 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: RSV dateStart: 20031201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFLZgQwgJcRm3wChGQuIBrCVxE9u8oA1tAolV1YCpPFmO40ClLilNO7bfxJ_kHCdtyRB74aVq4pO0xz7n8-XcCHnBuVMqjgwLcyUZAJ5kMgO9MpJnJsmFdD7b5_FHMRjI0UgN2wO3unWrXGKiB-q8snhGvhNjWpM4BnV4O_3BsGoUWlfbEhpXySaWzUY5F6P1hiuBtc0yUEamOzXMbRG63KLlUkrOzjqTkc_Z_zcy_zE1XXSbvGA79VPSwe3_ZeYOudUuRuluIz13yRVXbpHrh625fYvcbA71aBOrdI_8Akiks7VxntbngM2AERN6Op4tajr20SZNZCedNslk4W5JJ9VPRk2Z0xN_IMIwJ8SJo75SBW7W39BpNUfHJXgVLKOhoZ6zxtcE4Jg2sZwUXmooJlimmY--oFVBWwsT_sg5Ihd8KdC35z75crD_-d171lZ7YDZJ1ZyZpChg-wUrvFwIjFuBMeubUMGwClikSpsr56KCw44rhuFLIhuHuUltaGxfZbHlD8hGWZXuEaEyT7JQFCILuevHjhunsixSheAqx1pdAYmWw65tmwodK3JMtN8SyVQ3oqJBVLQXFX0WkFerZ6ZNIpBLqfdQmlaUmMTb36hm33SLCTotZGQSeEDyAtYIhZFWpTYxwDCHLikC8gxlUTcRsSso0ruirzj2AzDy0lMgGAED1rQxFdANmNarQ7ndoQQQsd3mpaDqFsRqvZbSgDxfNeOT6JhXumrhaTjMU7EQAXnYqMeKaS5wvujHAZEdxen0SrelHH_3Kc4xjxzGbAfk9VLH1v_r393--HI2npAbsdf-hEXJNtmYzxbuKblmT-fjetbz2OE_ZY9s7u0Phkc9f0QDV8MPh8OvcHX06fg3Cqh9Zg |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3db9MwELfGQICE-BhfgcGMBOIBoiV2UztICI2PadO6iocN9c04jgOVuqQ07bb-TUj8jdw5SUuG2NseeKtiO62vd7-7s--DkOec2zhmofaDNJY-AJ70ZQJypSVPdJQKaV21zy890e_LwSD-vEJ-NbkwGFbZYKID6rQweEa-ybCsCWMgDu_GP3zsGoW3q00LjYot9uz8BFy28u3uR_h_XzC2_engw45fdxXwTdSNp76OsgzMfLAkUiEwPwJM7I4OwPfmAowhadLY2jDjYNkzUL5RaFiQ6q4JtOnECTMc3nuJXIZtCXT2xGDp4EVgSzWJObK7WYIuDTHEF29KpeT-aUv5uR4Bf2uCP1Th2TDNM3e1TgVu3_rfiHeb3KyNbbpVSccdsmLzNXJ1vw4nWCM3qkNLWuVi3SU_AfLpZBl8QMs56B7AwBE9Hk5mJR26bJoqc5WOq2K58DSno-LEpzpP6ZE78PGx5sWRpa4TBx5GvKHjYoqBWfAqcBNgoJz6VSwNqBta5apSeKmmWECaJi67hBYZrW_Q8EvmiMzwIcPYpXvk8EJId5-s5kVuHxIq0ygJRCaSgNsOs1zbOEnCOBM8TrEXmUfChs2UqUu9Y8eRkXIun-yqijUVsKZyrKlOPfJqsWZcFTo5d_Z75N7FTCxS7h4Uk2-qxjzVzWSoI1ggeQY2UKalibsm0rBhDiTJPLKBvK-qjN8F1Kot0Yk50gE28tLNQLCFDRhd54wAGbBsWWvmemsmgKRpDzeCoWqQLtVSKjzybDGMKzHwMLfFzM3hoIeZEB55UInjYtNcoD7sMI_IlqC2qNIeyYffXQl3rJOHOekeed3I9PJ3_Zvsj87fxga5tnOw31O93f7eY3KdOeSJ_DBaJ6vTycw-IVfM8XRYTp463KLk60XL-m-79dCo |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZQQRUX3pRAoUZC4gBRkziJbW7lsQJRVpWAqjfLcWxYaZuskt1CfxN_khknmzblISFuq3i8G489n2fWM58JecKYlTKJdRiVUoQAeCIUBdiVFqzQWcmF9Wyfh_t8OhVHR_LgXBW_z3ZfH0l2NQ3I0lQtdxel60xc5Lst7FIxJs_iGaQQLAQv8nKKifQYr388HEKuDLybdanMb_uNtiPP2v8rNp_bnC4mTl44PfWb0uT6_w_nBrnWO6R0r1tBN8klW90imx_6I_fb5AfAIG3ODuRpewp4DLgwpyezZtXSma8w6ao56aIjkIWnFZ3X30Kqq5Ie-z9BQuSBOLbU306BAfoLuqjxJfGrwHWGhnYZdvklAMG0q9-k8KWaIqkyLXzFBa0d7U-V8EdOEa3gg8N8njvk8-TNp1dvw_6Gh9BkuVyGOnMOQi7w6krOsVYF1JHqSArOODimwpTS2tgxiLIS0EwWmyQqdW4ibVJZJIbdJRtVXdl7hIoyKyLueBExmyaWaSuLIpaOM1ni_VwBidcTrUxPf463cMyVD4NErrpZUDALys-C-h6QZ0OfRUf-8Vfpl7h-Bkkk7vYP6uaL6nFA5U7EOoMOgjnwC5wWRuYm0zBgBipxAdnB1ae6KtgBftQeTyVDPcBAnnoJBCAYgNF9HQWoAam8RpLbI0kADjNuXq9w1QNXqxJkD0oSjs2Ph2bsicl4la1XXobB3pRwHpCtziCGQTOOe0SaBESMTGWklXFLNfvqac2ROw7rtAPyfG0xZ-_1Z7Xf_zfxHbJ58Hqi9t9N3z8gVxNvc1kYZ9tkY9ms7ENyxZwsZ23zyAPJT-6pdPU |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=New+respiratory+syncytial+virus+immunization+products+in+low-+and+middle-income+countries%3A+potential+for+cost-effective+impact+on+a+high+burden+of+disease+in+young+infants&rft.jtitle=BMC+medicine&rft.au=Srikantiah%2C+Padmini&rft.au=Klugman%2C+Keith+P&rft.date=2023-05-15&rft.pub=Springer+Nature+B.V&rft.eissn=1741-7015&rft.volume=21&rft.spage=1&rft_id=info:doi/10.1186%2Fs12916-023-02883-x |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1741-7015&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1741-7015&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1741-7015&client=summon |